Ignite Creation Date:
2024-05-06 @ 12:51 PM
Last Modification Date:
2024-10-26 @ 1:05 PM
Study NCT ID:
NCT03869294
Status:
COMPLETED
Last Update Posted:
2020-03-04
First Post:
2019-03-08
Brief Title:
GS Regimen as the First-line Chemotherapy in Chinese Advanced PC Patients
Sponsor:
Zhejiang University
Organization:
Zhejiang University
Study Overview
Official Title:
Gemcitabine Plus S-1 as the First-line Chemotherapy in Chinese Patients With Advanced Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Gemcitabine plus S-1 GS prolonged progression-free survival PFS and greatly improved objective response rate ORR as well as disease control rate DCR of Asian patients with locally advanced and metastatic pancreatic cancer PC However limited data of GS regimen exist on the efficacy and safety in the treatment of Chinese patients with advanced PC To assess the efficacy and safety of gemcitabine plus S-1 GS regimen as the first-line chemotherapy in Chinese patients with advanced PC we designed this prospective study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None